Celularity Inc (CELUW)
Official siteBIOTECHNOLOGY • NASDAQ
Last updated: Jul 23, 2026 at 5:00 PM ET
Celularity Inc (CELUW) Financials: Revenue, Profit and Cash Flow
Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025, down 51.0% from the year before. That year, net income was -$91.80M with a net margin of -345.8%, operating cash flow was -$13.25M and free cash flow was -$13.25M. The quarter ended Mar 31, 2026 had revenue of $4.10M and net income of -$24.36M.
Revenue and Margins
Over the 7 years to Dec 2025, revenue grew from $17.55M, a compound annual rate of 6.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $26.55M | -51.0% | 76.0% | -230.9% | -345.8% |
| Dec 2024 | $54.22M | +138.1% | 72.4% | -70.7% | -106.8% |
| Dec 2023 | $22.77M | +26.7% | 29.7% | -335.9% | -862.0% |
| Dec 2022 | $17.98M | -15.7% | -9.4% | -142.4% | 79.0% |
| Dec 2021 | $21.34M | +49.4% | 54.8% | -511.2% | -469.3% |
| Dec 2020 | $14.28M | -32.5% | 65.5% | -1064.0% | -1458.4% |
| Dec 2019 | $21.15M | +20.5% | 70.1% | -1249.0% | -1001.9% |
| Dec 2018 | $17.55M | N/A | 62.7% | 0.0% | 0.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M | $21.15M | $17.55M |
| Cost of revenue | $6.36M | $14.99M | $16.02M | $19.66M | $9.65M | $4.93M | $6.32M | $6.55M |
| Gross profit | $20.19M | $39.23M | $6.75M | -$1.69M | $11.68M | $9.35M | $14.82M | $11.00M |
| Research and development | $15.03M | $17.39M | $30.46M | $78.36M | $88.35M | $52.71M | $46.05M | $29.06M |
| Operating income | -$61.31M | -$38.36M | -$76.48M | -$25.60M | -$109.06M | -$151.93M | -$264.13M | -$1.10K |
| Net income | -$91.80M | -$57.89M | -$196.29M | $14.19M | -$100.12M | -$208.23M | -$211.88M | -$1.10K |
| EBITDA | N/A | N/A | N/A | N/A | -$88.11M | N/A | -$70.98M | -$1.10K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.10M | $4.10M | $5.28M | $5.74M | $18.13M | $18.13M | $9.30M | $12.11M | $14.68M | $3.79M | $3.79M | $2.94M |
| Gross profit | $8.56M | -$3.27M | $3.27M | $494.00K | $10.79M | $10.79M | $5.41M | $2.50M | $13.04M | $184.00K | $184.00K | $2.14M |
| Operating income | -$22.06M | -$22.06M | -$12.90M | -$15.86M | -$9.28M | -$9.47M | -$11.53M | $13.31M | -$7.38M | -$99.26M | -$16.30M | -$42.48M |
| Net income | -$24.36M | -$24.36M | -$23.07M | -$24.52M | -$13.29M | -$13.29M | -$16.10M | $9.55M | -$22.01M | -$93.88M | -$93.88M | -$47.95M |
Balance Sheet
As of Dec 2025, short-term debt of $14.00M exceeded cash and equivalents by $7.83M. Shareholder equity was negative, at -$38.06M, as total liabilities of $145.39M exceeded total assets of $107.33M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $107.33M | $132.68M | $143.89M | $401.07M | $414.13M | $431.01M | $521.50M | $24.71K |
| Current assets | $12.32M | $20.56M | $19.79M | $33.50M | $37.24M | $72.16M | $36.81M | $24.71K |
| Cash and equivalents | $6.17M | $738.00K | $227.00K | $13.97M | $37.24M | $54.31M | $28.13M | $24.71K |
| Total liabilities | $145.39M | $123.84M | $102.93M | $202.16M | $314.71M | $412.30M | $383.63M | $150.56K |
| Short-term debt | $14.00M | $6.36M | N/A | $37.60M | $3.05M | $3.01M | N/A | N/A |
| Long-term debt | N/A | $35.93M | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | -$38.06M | $8.84M | $40.96M | $198.90M | $99.42M | $18.71M | $137.86M | -$125.85K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $107.33M | $107.33M | $114.24M | $120.28M | $132.68M | $132.68M | $128.84M | $143.89M | $143.82M | $157.19M | $157.19M | $246.42M |
| Total liabilities | $145.39M | $145.39M | $134.33M | $145.78M | $123.84M | $123.84M | $111.56M | $102.93M | $112.57M | $126.94M | $126.94M | $127.92M |
| Cash and equivalents | $6.17M | $6.17M | $120.00K | $863.00K | $738.00K | $738.00K | $133.00K | $227.00K | $1.90M | $273.00K | $273.00K | $3.08M |
| Shareholder equity | -$38.06M | -$38.06M | -$20.09M | -$25.50M | $8.84M | $8.84M | $17.28M | $40.96M | $31.25M | $30.25M | $30.25M | $118.50M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.25M | -$6.40M | -$38.69M | -$137.88M | -$110.10M | -$63.19M | -$1.10M | -$543 |
| Capital expenditures | $0 | $161.00K | $4.05M | $5.24M | $6.20M | $27.83M | $3 | $1.92M |
| Free cash flow | -$13.25M | -$6.56M | -$42.73M | -$143.11M | -$116.30M | -$91.03M | -$1.10M | -$1.92M |
| Dividends paid | $5.90M | $0 | N/A | $39.07M | N/A | N/A | N/A | N/A |
| Investing cash flow | N/A | $514.00K | N/A | -$5.24M | N/A | -$12.81M | -$286.85M | -$31.18M |
| Financing cash flow | $18.65M | $6.70M | $24.09M | $119.84M | $98.56M | $102.01M | $288.84M | $25.25K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.10M | -$5.10M | -$4.16M | -$999.00K | $1.59M | $1.59M | -$144.00K | -$4.34M | -$4.40M | -$8.32M | -$8.32M | -$11.03M |
| Capital expenditures | $0 | $0 | $56.00K | $1 | $56.00K | $56.00K | $35.00K | $580.00K | $39.00K | $228.00K | $228.00K | $31.00K |
| Free cash flow | -$5.10M | -$5.10M | -$4.21M | -$999.00K | $1.54M | $1.54M | -$179.00K | -$4.92M | -$4.44M | -$8.55M | -$8.55M | -$11.06M |
Frequently Asked Questions About CELUW
What is Celularity's annual revenue?
Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025.
How fast is Celularity's revenue growing?
Revenue was down 51.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.9%.
Is Celularity profitable?
No. Celularity reported net income of -$91.80M for the fiscal year ended Dec 31, 2025, with a net margin of -345.8%.
How much free cash flow does CELUW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.25M minus capital expenditures of $0 produced free cash flow of -$13.25M.
How much debt does Celularity have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $14.00M and cash and equivalents of $6.17M.
CELUW pages: Overview, Financials